Cart
sales@molnova.com
SR 19881
CAS No. 2213490-89-0
SR 19881( —— )
Catalog No. M21956 CAS No. 2213490-89-0
SR 19881 is a full agonist of ERRγ(EC50 value of 0.39 μM in a binding assay and an EC50 value of 4.7 μM in a cell-based assay).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 137 | Get Quote |
|
| 5MG | 192 | Get Quote |
|
| 10MG | 308 | Get Quote |
|
| 25MG | 519 | Get Quote |
|
| 50MG | 744 | Get Quote |
|
| 100MG | 1017 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSR 19881
-
NoteResearch use only, not for human use.
-
Brief DescriptionSR 19881 is a full agonist of ERRγ(EC50 value of 0.39 μM in a binding assay and an EC50 value of 4.7 μM in a cell-based assay).
-
DescriptionSR 19881 is a full agonist of ERRγ(EC50 value of 0.39 μM in a binding assay and an EC50 value of 4.7 μM in a cell-based assay).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetEstrogen Receptor/ERR
-
RecptorERRγ
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2213490-89-0
-
Formula Weight312.4
-
Molecular FormulaC19H24N2O2?
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCCN(CC)c1ccc(CCNC(=O)c2ccc(O)cc2)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Lin H , Doebelin C , Patouret, Rémi, et al. Design, synthesis, and evaluation of simple phenol amides as ERRγ agonists[J]. Bioorganic & Medicinal Chemistry Letters, 2018:S0960894X18301987.
molnova catalog
related products
-
Prinaberel
Prinaberel (ERB-041) is an effective and selective ERβ agonist and >200-fold selective for ERβ.
-
Estradiol benzoate
Estradiol benzoate is an estradiol analog which binds to the human, murine and chicken ERα with IC50 of 22-28 nM.
-
GDC-0927 racemate
GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) for treatment of metastatic hormone receptor-positive/HER2-negative breast cancer.
